Exelixis' cabozantinib shows OS benefit in RCC

Exelixis Inc. (NASDAQ:EXEL) said cabozantinib (XL-184) showed an overall survival (OS) benefit over Afinitor everolimus from Novartis AG (NYSE:NVS; SIX:NOVN) in the Phase III METEOR trial to treat advanced or metastatic renal cell carcinoma.

The company said cabozantinib led to a "highly statistically significant and clinically meaningful increase in OS" vs. Afinitor in METEOR, which enrolled patients whose disease had progressed after treatment with a VEGF receptor tyrosine kinase inhibitor (TKI). Exelixis plans to present detailed data at a medical meeting this year. ...